Immunic Inc, which is co-located in the US and Germany, has raised approximately $60 million in an oversubscribed private equity financing to support clinical development of its small molecule drugs for chronic inflammatory and autoimmune diseases. The newest financing extends the company’s cash runway into the fourth quarter of 2024.
